Inspire Medical Systems, Inc. (NYSE:INSP) Given Average Recommendation of “Hold” by Brokerages

Shares of Inspire Medical Systems, Inc. (NYSE:INSP) have been given an average rating of “Hold” by the twenty-one ratings firms that are presently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $81.2632.

A number of equities analysts have recently issued reports on the company. Zacks Research raised Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Piper Sandler cut Inspire Medical Systems from an “overweight” rating to a “neutral” rating and lowered their price objective for the stock from $85.00 to $55.00 in a research report on Tuesday, May 5th. Summit Redstone set a $39.00 target price on Inspire Medical Systems in a research note on Friday, May 22nd. Stifel Nicolaus reduced their target price on Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Finally, Freedom Capital raised Inspire Medical Systems to a “strong-buy” rating in a research report on Tuesday, June 30th.

Institutional Investors Weigh In On Inspire Medical Systems

A number of large investors have recently modified their holdings of the business. CWM LLC increased its holdings in shares of Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after acquiring an additional 242 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares in the last quarter. Havemeyer Place LP acquired a new stake in Inspire Medical Systems in the 4th quarter worth approximately $39,000. V Square Quantitative Management LLC purchased a new stake in Inspire Medical Systems during the 4th quarter worth approximately $40,000. Finally, Smartleaf Asset Management LLC grew its position in Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after purchasing an additional 205 shares during the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Stock Down 2.0%

NYSE INSP opened at $50.53 on Friday. The firm has a market cap of $1.46 billion, a PE ratio of 11.25, a price-to-earnings-growth ratio of 5.22 and a beta of 0.71. The company has a 50 day moving average price of $44.36 and a 200 day moving average price of $58.80. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The company had revenue of $204.58 million during the quarter, compared to analysts’ expectations of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. Inspire Medical Systems’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities research analysts anticipate that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.